Dodji Modjinou, MD
Rheumatology · Henderson, NVNPI 1710120068
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,975 of the $4,110 with a category attached, or 72.4%. Sobi, Inc accounts for 75.7% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $3,435, more than ten times the $114 reported in 2019.
Across 14 payments — averaging $293.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$3K
- Sanofi$437
- Cardinal Health 110 LLC$127
- Novartis$125
- Boehringer Ingelheim$114
- AbbVie$108
- plus $89 from 3 others
What the payments were for
- Consulting fees$2,97572%
- Food & beverage$1,13528%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 2 | $3,110 |
| Sanofi | 4 | $437 |
| Cardinal Health 110 LLC | 1 | $127 |
| Novartis | 1 | $125 |
| Boehringer Ingelheim | 1 | $114 |
| AbbVie | 2 | $108 |
| Cardinal Health Inc | 1 | $33 |
| Amgen | 1 | $29 |
| Johnson & Johnson | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,110 in reported general payments places this provider in the 65th percentile of 43 rheumatology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 22 | $161,723 |
| Xeljanz XrTofacitinib Citrate | 17 | $98,485 |
| Humira(Cf) PenAdalimumab | 14 | $92,626 |
| Orencia ClickjectAbatacept | 14 | $78,139 |
| Actemra ActpenTocilizumab | 14 | $73,761 |
| Hydroxychloroquine Sulfate | 147 | $9,004 |
| MethotrexateMethotrexate Sodium | 243 | $6,656 |
| Mycophenolate Mofetil | 26 | $4,231 |
| Azathioprine | 26 | $2,927 |
| Leflunomide | 40 | $2,471 |
| Sulfasalazine | 55 | $2,076 |
| Prednisone | 227 | $1,792 |
| Pilocarpine Hcl | 33 | $1,345 |
| Gabapentin | 62 | $1,198 |
| Methylprednisolone | 81 | $988 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Henderson
- Christianne YungHenderson$101K
- Scott HarrisHenderson$2K
- Mitchell FormanHenderson$588
- Michael OhanlanHenderson$138
- Kenneth GrantHenderson$129
- Ewa OlechLas Vegas$287K
- Walter ChathamLas Vegas$197K
- George KellyLas Vegas$185K
- Nasim DaoudLas Vegas$109K
- Carolyn DenneheyReno$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.